Atezolizumab Triplet Therapy for BRAF V600-Mutant Melanoma: Paolo A. Ascierto, MD

Recently, the FDA approved a new indication for atezolizumab (Tecentriq®, Genentech) in combination with vemurafenib (Zelboraf®, Genentech and Daiichi-Sankyo) and cobimetinib (Cotellic®, Genentech) for the treatment of BRAF V600-mutant advanced melanoma. In this interview with i3 Health, Paolo A. Ascierto, MD, principal investigator of the IMspire150 trial, on which the approval was based, discusses the approval's significance and the most promising research developments in the treatment of BRAF...
Continue reading

Atezolizumab Combo Approved in BRAF V600-Mutant Melanoma

The FDA has approved a new indication for atezolizumab (Tecentriq®, Genentech) in combination with cobimetinib (Cotellic®, Genentech) and vemurafenib (Zelboraf®, Genentech and Daiichi-Sankyo) for the treatment of BRAF V600-mutated advanced melanoma. The approval was granted under a supplemental Biologics License Application (sBLA) with priority review. The approval was based on data from the double-blind, international phase 3 IMspire150 trial (NCT02908672), for which 514 patients with unresecta...
Continue reading

Can Metabolic Regulators Fight Metastatic Melanoma?

Vemurafenib, an inhibitor of mitogen-activated protein kinase signaling downstream of BRAFV600E, can be successfully used to treat patients with metastatic melanoma. However, it produces a high incidence of therapeutic resistance. New strategies are needed to treat vemurafenib-resistant melanoma, so researchers used two bioactive compound libraries and identified two possible targets: deguelin and rotenone. "Breakthroughs in understanding the molecular basis for the disease have led to a couple ...
Continue reading

Copyright © 2021 Oncology Data Advisor. All rights reserved.